Amedisys (NASDAQ:AMED) Reaches New 12-Month Low – Here’s What Happened

Amedisys, Inc. (NASDAQ:AMED) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $86.31 and last traded at $87.91, with a volume of 514067 shares changing hands. The stock had previously closed at $91.24.

Amedisys Stock Down 4.4 %

The company’s 50-day simple moving average is $94.63 and its two-hundred day simple moving average is $95.59. The firm has a market capitalization of $2.86 billion, a P/E ratio of 34.67, a P/E/G ratio of 1.92 and a beta of 0.73. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19.

Amedisys (NASDAQ:AMED) last announced its earnings results on Wednesday, November 6th. The health services provider reported $1.00 EPS for the quarter, missing analysts’ consensus estimates of $1.19 by ($0.19). The company had revenue of $587.67 million during the quarter, compared to the consensus estimate of $586.75 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. Amedisys’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.98 earnings per share. As a group, research analysts expect that Amedisys, Inc. will post 4.55 earnings per share for the current year.

Institutional Investors Weigh In On Amedisys

A number of institutional investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD grew its stake in Amedisys by 0.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 31,199 shares of the health services provider’s stock valued at $2,876,000 after acquiring an additional 255 shares in the last quarter. California State Teachers Retirement System grew its holdings in shares of Amedisys by 65.8% in the first quarter. California State Teachers Retirement System now owns 54,592 shares of the health services provider’s stock valued at $5,031,000 after purchasing an additional 21,671 shares in the last quarter. Cetera Investment Advisers raised its stake in Amedisys by 37.6% during the first quarter. Cetera Investment Advisers now owns 18,005 shares of the health services provider’s stock valued at $1,659,000 after purchasing an additional 4,917 shares in the last quarter. Cetera Advisors LLC bought a new position in Amedisys during the first quarter valued at $1,556,000. Finally, SG Americas Securities LLC grew its stake in shares of Amedisys by 41.6% in the 2nd quarter. SG Americas Securities LLC now owns 38,315 shares of the health services provider’s stock worth $3,517,000 after buying an additional 11,264 shares in the last quarter. Hedge funds and other institutional investors own 94.36% of the company’s stock.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.